Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000347055

Medchemexpress LLC Sorafenib-d3 (Donafenib; Bay 43-9006-d3) | 1130115-44-4 | 99.57% | 467.84 | 25 MG
SDP

Catalog No. 5000347055
Encompass_Preferred

Sorafenib-d3 (Donafenib) is a deuterated compound of Sorafenib, recognized as the first deuterium-generation tumor suppressor small molecule. Sorafenib itself is a multikinase inhibitor with IC50s of 6 nM for Raf-1, 20 nM for B-Raf, and 22 nM for VEGFR-3. This compound is intended for research use only. Potential advantages of deuterated compounds like Sorafenib-d3 include:

  • Extends the in vivo half-life.
  • Improves oral bioavailability.
  • Enhances metabolic characteristics.
  • Improves drug safety.
  • Preserves therapeutic properties.

Catalog No. 50-003-47055 Supplier Medchemexpress LLC Supplier No. 25MGHY10201S
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Sorafenib-d3 (Donafenib) is a deuterated compound of Sorafenib, recognized as the first deuterium-generation tumor suppressor small molecule. Sorafenib itself is a multikinase inhibitor with IC50s of 6 nM for Raf-1, 20 nM for B-Raf, and 22 nM for VEGFR-3. This compound is intended for research use only. Potential advantages of deuterated compounds like Sorafenib-d3 include:

  • Extends the in vivo half-life.
  • Improves oral bioavailability.
  • Enhances metabolic characteristics.
  • Improves drug safety.
  • Preserves therapeutic properties.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.